Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ashler et MansonXPAR:MLAEM 80 Days Payable is 133.18 as of Dec. 2024, which is 85% below its 10-year median of 883.48. GuruFocus rates XPAR:MLAEM with a GF Score™ of 80/100 and a GF Value™ of €2.62 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 56 Insurance companies, Ashler et Manson ranks better than 69.64% on this metric.
The historical rank and industry rank for Ashler et Manson's Days Payable or its related term are showing as below:
XPAR:MLAEM'
s Days Payable Range Over the Past 10 Years
Min: 87.6 Med: 883.48 Max: 5135.47
Current: 133.18
During the past 10 years, Ashler et Manson's highest Days Payable was 5135.47. The lowest was 87.60. And the median was 883.48.
XPAR:MLAEM's Days Payable is ranked better than 69.64% of 56
companies
in the Insurance industry
Industry Median: 58.52
vs XPAR:MLAEM: 133.18
Ashler et Manson's Days Payable
declined
from Dec. 2022 (3,172.55) to Dec. 2024 (133.18).
It may suggest that Ashler et Mansonaccelerated paying its suppliers.
Ashler et Manson Days Payable Related Terms
Ashler et Manson Days Payable Historical Data
* Premium members only.
The historical data trend for Ashler et Manson's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:MLAEM vs MRSH, AON, AJG: Days Payable Comparison
For the Insurance Brokers subindustry, Ashler et Manson's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ashler et Manson Days Payable vs Insurance Industry
For the Insurance industry and Financial Services sector, Ashler et Manson's Days Payable distribution charts can be found below:
* The bar in red indicates where Ashler et Manson's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Ashler et Manson's Days Payable for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ashler et Manson (XPAR:MLAEM) has a Days Payable of 133.18 as of Dec. 2024. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Ashler et Manson and its competitors. This is 85% below median its historical median of 883.48. Over the past decade, Ashler et Manson's Days Payable has ranged from 87.60 to 5,135.47. According to the industry distribution chart, Ashler et Manson ranks #17 out of 56 companies in the Insurance industry, placing it in the top 30.4%.
Is Ashler et Manson's Days Payable too high?
Ashler et Manson's current Days Payable of 133.18 is 85% below median its 10-year median of 883.48. Over the past 10 years, this metric has ranged from a low of 87.60 to a high of 5,135.47. The Insurance industry median Days Payable is 58.52. Ashler et Manson's value of 133.18 is 127.6% above this industry median. Based on the distribution chart, Ashler et Manson ranks #17 out of 56 companies in the Insurance industry, which is above the industry midpoint. Overall, Ashler et Manson has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ashler et Manson's Days Payable compare to MRSH and AON?
According to the Insurance industry distribution chart, Ashler et Manson ranks #17 out of 56 companies for Days Payable. This puts Ashler et Manson in the upper half of its industry. The industry median Days Payable is 58.52. Ashler et Manson's value of 133.18 is 127.6% above this benchmark. Historically, Ashler et Manson's own Days Payable has ranged from 87.60 to 5,135.47 over the past decade. While the company's 10-year median is 883.48 vs. the industry median of 58.52, Ashler et Manson has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for an Insurance company?
The median Days Payable among Insurance companies is 58.52, based on 56 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ashler et Manson's current Days Payable of 133.18 is 127.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Ashler et Manson and its competitors. For the Insurance industry, the median Days Payable is 58.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ashler et Manson's current Days Payable is 133.18, which is 85% below median its own 10-year median of 883.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ashler et Manson stock overvalued right now?
Based on GuruFocus' analysis, Ashler et Manson (XPAR:MLAEM) is currently considered Modestly Overvalued. The stock's GF Value™ is €2.62, compared to a current price of €3.04 — trading 16% above its estimated fair value. The current Days Payable is 133.18, which is 85% below median its 10-year median of 883.48 and 127.6% above the Insurance industry median of 58.52. Ashler et Manson's overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Ashler et Manson (XPAR:MLAEM), the current Days Payable is 133.18 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ashler et Manson (XPAR:MLAEM) Overvalued in 2026?
Based on GuruFocus' analysis, Ashler et Manson stock appears to be overvalued.
The current stock price of €3.04 is trading 16% above its estimated GF Value™ of €2.62.
GuruFocus considers Ashler et Manson to be Modestly Overvalued.
Key valuation signals for XPAR:MLAEM:
Days Payable: 133.18 (85% below median its 10-year median of 883.48)
GF Value™: €2.62 vs. price of €3.04 (16% above fair value)
Industry Position: 127.6% above the Insurance median (#17 of 56)
No single metric tells the full story. See the XPAR:MLAEM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:MLAEM has been successfully added to your 
